Novel and potent small-molecule urotensin II receptor agonists

Bioorganic and Medicinal Chemistry

Volumn 17, Issue 13, 2009, Pages 4657-4665

  Lehmann, Fredrik ^a   Currier, Erika A ^d   Clemons, Bryan ^d   Hansen, Lars K ^b   Olsson, Roger ^c   Hacksell, Uli ^d   Luthman, Kristina ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b UNIVERSITY OF TROMSØ   (Norway)

^c ACADIA Pharmaceuticals AB   (Sweden)

^d ACADIA PHARMACEUTICALS INC   (United States)

Author keywords

Agonists; Parallel synthesis; R SAT; SAR; Urotensin II

Indexed keywords

4 CHROMANONE DERIVATIVE; AC 7954; BENZAMIDE DERIVATIVE; FL 104; N [1 (4 CHLOROPHENYL) 3 (DIMETHYLAMINO)PROPYL] 4 PHENYLBENZAMIDE; N [3 DIMETHYLAMINO 1 (2 NAPHTHYL)PROPYL] 4 (4 CHLOROPHENYL)BENZAMIDE; UNCLASSIFIED DRUG; UROTENSIN II; UROTENSIN II RECEPTOR;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; ENANTIOSELECTIVITY; HUMAN; NONHUMAN; STRUCTURE ACTIVITY RELATION;

ANIMALS; BENZAMIDES; CRYSTALLOGRAPHY, X-RAY; HUMANS; MICE; MODELS, MOLECULAR; MOLECULAR STRUCTURE; NIH 3T3 CELLS; RECEPTORS, G-PROTEIN-COUPLED; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 66449132432     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2009.04.062     Document Type: Article

References (23)

1. Ames R.S., Sarau H.M., Chambers J.K., Willette R.N., Alyar N.V., Romanic A.M., Louden C.S., Foley J.J., Sauermelch C.F., Coatney R.W., Ao Z.H., Disa J., Holmes S.D., Stadel J.M., Martin J.D., Liu W.S., Glover G.I., Wilson S., McNulty D.E., Ellis C.E., Elshourbagy N.A., Shabon U., Trill J.J., Hay D.W.P., Ohlstein E.H., Bergsma D.J., and Douglas S.A. Nature 402 (1999) 282
2. Douglas S., Aiyar N.V., Ohlstein E.H., and Willette R.N. Eur. Heart J. 21 (2000) 229
3. Dhanak D., Neeb M.J., and Douglas S.A. Annu. Rep. Med. Chem. 38 (2003) 99
4. Thanassoulis G., Huyhn T., and Giaid A. Peptides 25 (2004) 1789
5. Russell F.D. Pharmacol. Ther. 103 (2004) 223
6. Onan D., Hannan R.D., and Thomas W.G. Trends Endocrin. Met. 15 (2004) 175
7. Joyal D., Huynh T., Aiyar N., Guida B., Douglas S., and Giaid A. Int. J. Cardiol. 108 (2006) 31
8. Douglas S., Dhanak D., and Johns D.G. Trends Pharmacol. Sci. 25 (2004) 76
9. Lescot E., Bureau R., and Rault S. Peptides 29 (2008) 680 and references cited therein
10. Lehmann F., Pettersen A., Currier E.A., Sherbukhin V., Olsson R., Hacksell U., and Luthman K. J. Med. Chem. 49 (2006) 2232
11. Croston G.E., Olsson R., Currier E.A., Burstein E.S., Weiner D., Nash N., Severance D., Allenmark S.G., Thunberg L., Ma J.N., Mohell N., O'Dowd B., Brann M.R., and Hacksell U. J. Med. Chem. 45 (2002) 4950
12. Lehmann F., Currier E.A., Olsson R., Hacksell U., and Luthman K. Bioorg. Med. Chem. 13 (2005) 3057
13. Sajiki H., Kurita T., Kozaki A., Zhang G., Kitamura Y., Maegawa T., and Hirota K. Synthesis (2005) 537 (Erratum Synthesis-Stuttgart 2005, 852)
14. Lehmann F., Lake L., Currier E.A., Olsson R., Hacksell U., and Luthman K. Eur. J. Med. Chem. 42 (2007) 276
15. Bräuner-Osborne H., and Brann M.R. Eur. J. Pharmacol. 295 (1996) 93
16. Burstein E.S., Bräuner-Osborne H., Spalding T.A., Conklin B.R., and Brann M.R. J. Neurochem. 68 (1997) 525
17. Burstein E.S., Spalding T.A., and Brann M.R. Mol. Pharmacol. 51 (1997) 312
18. (a) Spalding, T. A.; Burstein, E. S.; Jorgensen, H. B.; Hilleubanks, D.; Brann, M. R. Life Sci. 1995, 56, 1021; (b) Burstein, E. S.; Piu, F.; Ma, J. N.; Weissman, J. T.; Currier, E. A.; Nash, N. R.; Weiner, D. M.; Spalding, T. A.; Schiffer, H. H.; Del Tredici, A. L.; Brann, M. R. Curr. Pharm. Des. 2006, 12, 1717.
19. Enraf-Nonius. CAD4-PC Software. Version 1.1 Enraf-Nonius; Delft, The Netherlands, 1992.
20. McArdle P., and Higgins T. XCAD4 (1995), National University of Ireland, Galway, Ireland
21. McArdle, P. OSCAIL-X for Windows.Version 1.0.7; Crystallography Centre, Chemistry Department, NUI: Galway, Ireland, 2005.
22. Sheldrick G.M. SHELXL97 and SHELXS97 (1997), University of Göttingen, Germany
23. Flack H.D.A. Acta Crystallogr., Sect. A 39 (1983) 876